I'm LongbridgeAI, I can summarize articles.Moderna rose 18.41% this week to close at $225, up from the prior Friday’s close of $190.01. The S&P 500 added 1.15% over the same period, leaving Moderna about 17.26 percentage points ahead of the benchmark. The week was front-loaded with volatility: Monday opened at $191.41, touched an intraday high of $205.77 and closed at $203.21; Tuesday gave back the gains to end at $187.46. Wednesday and Thursday traded in a range between $182.50 and $199.92.
The Week
Moderna rose 18.41% this week to close at $225, up from the prior Friday’s close of $190.01. The S&P 500 added 1.15% over the same period, leaving Moderna about 17.26 percentage points ahead of the benchmark. The week was front-loaded with volatility: Monday opened at $191.41, touched an intraday high of $205.77 and closed at $203.21; Tuesday gave back the gains to end at $187.46. Wednesday and Thursday traded in a range between $182.50 and $199.92. Friday brought a sharp rally to $225, the week’s high, with volume expanding. Weekly amplitude was 22.2% and average daily volume was roughly double the 60-day median.
Key Events
The week revolved around an executive appointment and cancer-vaccine partnerships. After Monday’s advance, the newly named COO drew market attention, and the stock pulled back on Tuesday and into Wednesday. On Wednesday, Tempus announced a multi-year collaboration with Moderna and Merck to support commercialisation of the V940 melanoma vaccine, while Moderna highlighted its COVID-era manufacturing playbook at CPHI 2026. Friday was the catalyst: Moderna joined the Nasdaq 100, BofA raised its price objective to $200, market participants positioned for melanoma vaccine data at ESMO, and a planned national cancer vaccine effort at NIH lifted biotech sentiment. Moderna rallied more than 10% intraday to a fresh 52-week high.
Analyst Ratings
As of 9 October 2026, 23 brokers cover Moderna: 4 rate it buy, 1 overweight, 15 hold, 1 underweight and 2 sell. The consensus rating is hold, with a consensus target price of $122.67, about 45.48% below the current $225. Targets span a wide range, from $45 to $200. Among 508 biotech names, Moderna ranks 18th by industry rating.
The Week Ahead
The macro calendar picks up next week: NFIB small-business optimism and existing home sales arrive on Tuesday 13 October, followed by CPI and core CPI on Wednesday 14 October. From this week’s thread, the market will also be watching whether the Nasdaq 100 inclusion attracts sustained flows, whether melanoma vaccine data at ESMO meet expectations, and how the NIH cancer vaccine initiative develops.
In Short
A strong rally and heavy volume this week sit alongside a neutral broker consensus and a consensus target about 40% below spot. That gap is the core tension: the Nasdaq 100 inclusion may bring passive flows, but the valuation case is less clear against a still loss-making earnings profile and a very large year-to-date gain. The next checkpoints are post-inclusion demand, the ESMO readout, and whether macro CPI data pressure the growth-stock valuation framework.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.